Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07667829). This is a study registration, not published results. Lead sponsor: China National Center for Cardiovascular Diseases. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 75 participants (ESTIMATED). Conditions: Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Hypertension, Pulmonary. Interventions: DRUG: Norepinephrine; DRUG: Dopamine; DRUG: Epinephrine. Primary outcome measures: All-cause mortality within 28 days , 28 days after enrolment. Brief summary: Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring